The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday.

Former Trump administration health official Joe Grogan applauds Biden proposal that Medicare and Medicaid cover GLP-1 weight-loss drugs — but says subjecting Wegovy to price controls is a bad move.

Hays and her husband who have a Medicare Part D drug plan. As a result, she expects to shell out a lot less at the pharmacy counter in 2025.   “That $2,000 cap,” which will be adjusted annually for inflation,

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts before President-elect Trump’s inauguration. The Centers for Medicare

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

The price negotiations almost assures billions of dollars in savings for taxpayers.

The U.S. healthcare system is confusing, but Medicare can be particularly hard to figure out. This is true for retirees and soon-to-be retirees. From gaps in coverage to having to enroll even if

This big adjustment that will hit the Social Security program in 2025 will impact Medicare and the amount that beneficiaries receive.

Events, activities and meetings in the coming week.